Selected article for: "flow velocity and valve disease"
Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018
  • Document date: 2018_10_25
    • ID: 60ceejq1_55
    Snippet: Study results suggest that CvRD is present in CHF cats with primary cardiomyopathy. Furthermore, SDMA is a novel biomarker in cats with CHF and primary CM that could be used for disease management and prognostication. As a consequence of the turbulent high-velocity flow and changes in fluid shear stress around the mitral valve, changes in platelet function may be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aim of t.....
    Document: Study results suggest that CvRD is present in CHF cats with primary cardiomyopathy. Furthermore, SDMA is a novel biomarker in cats with CHF and primary CM that could be used for disease management and prognostication. As a consequence of the turbulent high-velocity flow and changes in fluid shear stress around the mitral valve, changes in platelet function may be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aim of this study is to investigate whether the changes in coagulability vary with the severity of MMVD in dogs.

    Search related documents:
    Co phrase search for related documents
    • disease management and mitral valve disease: 1
    • disease management and novel biomarker: 1, 2
    • disease management and platelet function: 1
    • mitral valve and MMVD mitral valve disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mitral valve and MMVD severity: 1, 2, 3, 4
    • mitral valve and myxomatous MMVD mitral valve disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mitral valve and novel biomarker: 1
    • mitral valve and platelet function: 1
    • mitral valve disease and MMVD mitral valve disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mitral valve disease and MMVD severity: 1, 2, 3, 4
    • mitral valve disease and myxomatous MMVD mitral valve disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mitral valve disease and novel biomarker: 1
    • MMVD mitral valve disease and myxomatous MMVD mitral valve disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • MMVD severity and myxomatous MMVD mitral valve disease: 1, 2
    • novel biomarker and platelet function: 1, 2